Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements (Tables)

v3.19.1
Research and Development Agreements (Tables)
3 Months Ended
Mar. 31, 2019
Schedule of Research and Development Revenues Disaggregated by Location

Research and Development revenue is attributable to regions based on the location of our collaboration partner's parent company headquarters.  Research and Development revenues disaggregated by location were as follows (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Japan

 

$

6,413

 

 

$

163

 

United States

 

 

 

 

 

68

 

Total Research and Development Revenue

 

$

6,413

 

 

$

231

 

 

Takeda Pharmaceuticals Inc  
Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements

Research and development revenue from related party relates to revenue from research and development agreements with Takeda Pharmaceuticals, Inc (“Takeda”) and were as follows (in thousands):

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Takeda Collaboration Agreement

 

$

 

 

$

11

 

Takeda Individual Project Agreement

 

 

54

 

 

 

 

Takeda Development and License Agreement

 

 

6,114

 

 

 

 

Takeda Multi-Target Agreement

 

 

245

 

 

 

152

 

Total Research and Development Revenue

 

$

6,413

 

 

$

163

 

Schedule of Deferred Revenue and Accounts Receivable Balances from the Research and Development Agreements

Deferred revenue and accounts receivable balances from the research and development agreements with Takeda were as follows (in thousands):

 

 

March 31, 2019

 

 

December 31, 2018

 

Assets

 

 

 

 

 

 

 

 

Unbilled revenue

 

$

295

 

 

240

 

Liabilities

 

 

 

 

 

 

 

 

Deferred revenue, current

 

 

19,307

 

 

 

26,231

 

Deferred revenue, non-current

 

 

2,065

 

 

 

2,670

 

Total deferred revenue

 

$

21,372

 

 

$

28,901